Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-23
2007-10-23
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S326000, C514S341000, C514S361000, C514S365000, C514S374000, C514S397000, C514S406000, C544S405000, C546S211000, C546S275400, C548S127000, C548S200000, C548S236000, C548S312400
Reexamination Certificate
active
11399379
ABSTRACT:
Drugs, in particular, pyrazole derivatives represented by the following general formula (I) which have a calcium release-activated calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-activated calcium channel inhibitors containing the above compounds as the active ingredient,(in the formula, each symbol has the following meaning:D: pyrazolyl which may have 1 to 3 substituents selected from the group consisting of -Alk, -lower alkenyl, -lower alkynyl, -halogeno-lower alkyl, -Alk-cycloalkyl, -Alk-O-Alk, -cycloalkyl, —O-Alk, —COOH, —COO-Alk and -Hal,n: 0 or 1,B: phenylene, a nitrogen-containing, divalent, saturated ring group, or a monocyclic, divalent heteroaromatic ring group which may be substituted with Alk,X: —NR1—CR2R3—, —CR2R3—NR1—, —NR1—SO2—, —SO2—NR1— or —CR4═CR5—, andA: benzene ring which may have one or more substituents; mono-, di- or tricyclic fused heteroaryl which may have one or more substituents; cycloalkyl which may have one or more substituents; a nitrogen-containing, saturated ring group which may have one or more substituents; lower alkenyl which may have one or more substituents; lower alkynyl which may have one or more substituents; or Alk which may have one or more substituents).
REFERENCES:
patent: 4728653 (1988-03-01), Campbell et al.
patent: 5403838 (1995-04-01), Reinhard et al.
patent: 5571821 (1996-11-01), Vitukudi et al.
patent: 5712279 (1998-01-01), Biller et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6348480 (2002-02-01), Kubota et al.
patent: 6506747 (2003-01-01), Betageri et al.
patent: 6624309 (2003-09-01), Lloyd et al.
patent: 6686318 (2004-02-01), Andree et al.
patent: 6958339 (2005-10-01), Kubota et al.
patent: 2001/0044445 (2001-11-01), Bamaung et al.
patent: 2249542 (1999-04-01), None
patent: 34 01 911 (1985-01-01), None
patent: 64-55557 (1989-03-01), None
patent: 1-287071 (1989-11-01), None
patent: 03/77868 (1991-04-01), None
patent: 3-141261 (1991-06-01), None
patent: 4-234851 (1992-08-01), None
patent: 10-72434 (1998-03-01), None
patent: WO 85/04878 (1985-11-01), None
patent: WO 96/10559 (1996-04-01), None
patent: WO 96/23783 (1996-08-01), None
patent: WO 96/31517 (1996-10-01), None
patent: WO 97/05131 (1997-02-01), None
patent: WO 98/37069 (1998-08-01), None
patent: WO 99/51580 (1999-10-01), None
patent: WO 99/62885 (1999-12-01), None
Bartroli et al,J. Med. Chem., 4(11):1855-1868 (1998).
Wright et al,J. Med. Chem., 7(1):102-105 (1964).
Okazaki et al, “Nonlinear Optical Material and Triazole Compound”, Chemical Abstract No. 325369 vol. 123, No. 24 (Dec. 11, 1995).
Nicolai et al,Chem. Pharm. Bull., 42(8):1617-1630 (1994).
Badachikar et al,Indian J. Chem., 25B:1079-1080 (1996).
Mokhtar et al,Pharmazie, 33(10):648-651 (1978).
Cacchi et al, CAPLUS Abstract, 127:293164 (Synlett (1997), (8), 959-961), 1997.
Sykulski et al, CAPLUS Abstract, 91:74524, 1979.
Patel et al,Indian J. Chem., 29B:836-842 (1990).
Mizukawa et al, Chemical Abstract 111:205323, 1989.
Putney et al,J. of Cell Science, 114(12):2223-2229 (2001).
McDyer et al,J. of Immunology, 169:2736-2746 (2002).
Elgert, Autoimmunity, Immunology: Understanding the Immune System, pp. 315-330 (1996).
Wachlin et al,J. of Autoimmunity, 20:303-312 (2003).
Bremner et al,Expret Opin. Pharmacother., 3(7):809-825 (2002).
Singh et al,British Journal of Surgery, 88:1558-1569 (2001).
Robinson,Eur. J. Surg. Suppl., 582:90-98 (1998).
Beers et al, Crohn's Disease, Ulcerative colitis, The Merck Manual of Diagnosis and Therapy, Seventeenth Edition (online), 1999.
Finar et al, Chem. Abstract 55:25921f (1961).
Bouchet et al, Chem. Abstract 85:5545w (1976).
Patel et al, Chem. Abstract 114:23862u (1991).
Kawamura et al, Chem. Abstract 128:230375 (1998).
Funatsu Masashi
Ishikawa Jun
Kawazoe Souichirou
Kubota Hirokazu
Okamoto Yoshinori
Astellas Pharma Inc.
Rao Deepak
LandOfFree
Pyrazole derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazole derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3886767